Association of the Expression Level of miR-16 with Prognosis of Solid Cancer Patients: A Meta-Analysis and Bioinformatic Analysis

Table 3

HRs and 95% CIs of solid cancer patients with low miR-16 expression level in a Kaplan-Meier plotter database.

Cancer types	Sample size	HR (95% CI)	value
Total	7642	1.10 (1.00-1.19)	0.033
Digestive system
EAC	89	0.70 (0.39-1.27)	0.237
ESCC	95	0.56 (0.26-1.22)	0.143
LIHC	371	0.68 (0.48-0.96)	0.029
PAAD	178	1.67 (1.10-2.56)	0.015
READ	160	1.00 (0.46-2.17)	0.991
STAD	431	1.15 (0.85-1.56)	0.353
Subtotal	1324	0.93 (0.66-1.30)	0.682
Reproductive system
BRCA	1076	1.22 (0.88-1.69)	0.230
CSCC	307	1.52 (0.94-2.44)	0.081
OC	485	1.09 (0.86-1.35)	0.495
TGCT	134	0.97 (0.14-7.14)	0.978
UCEC	537	1.49 (0.97-2.27)	0.065
Subtotal	2539	1.21 (1.03-1.42)	0.017
Urinary system
BLCA	408	1.23 (0.92-1.67)	0.161
KIRC	516	0.93 (0.68-1.25)	0.613
KIRP	290	0.95 (0.53-1.72)	0.880
Subtotal	1214	1.06 (0.86-1.29)	0.583
Respiratory system
LUSC	472	1.12 (0.85-1.49)	0.434
LUAD	504	1.15 (0.86-1.54)	0.347
Subtotal	976	1.13 (0.93-1.39)	0.222
Other system
HNSC	522	1.13 (0.93-1.39)	0.053
THCA	506	1.47 (0.54-4.00)	0.450
PCPG	179	0.22 (0.03-1.96)	0.138
SARC	259	0.65 (0.43-0.96)	0.031
THYM	123	7.69 (0.97-50.0)	0.022
Subtotal	1589	1.08 (0.95-1.23)	0.810

BLCA: bladder carcinoma; BRCA: breast cancer; CSCC: cervical squamous cell carcinoma; EAC: esophageal adenocarcinoma; ESCC: esophageal squamous cell carcinoma; HNSC: head-neck squamous cell carcinoma; KIRC: kidney renal clear cell carcinoma; KIRP: kidney renal papillary cell carcinoma; LIHC: liver hepatocellular carcinoma; LUAD: lung adenocarcinoma; LUSC: lung squamous cell carcinoma; OC: ovarian cancer; PAAD: pancreatic ductal adenocarcinoma; PCPG: pheochromocytoma and paraganglioma; READ: rectum adenocarcinoma; SARC: sarcoma; STAD: stomach adenocarcinoma; TGCT: testicular germ cell tumor; THYM: thymoma; THCA: thyroid carcinoma; UCEC: uterine corpus endometrial carcinoma.